TNYA
Tenaya Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.68
−1.52%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -3.7%
- EBIT
- -2.8%
- EPS
- +44.8%
- Free cash flow
- +7.7%
- Operating cash flow
- +7.0%
Forward estimates
Based on analyst estimates
- Revenue
- +359.7%
- EBITDA
- +14.9%
- EPS
- +24.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- +20.0%
- EBIT
- +19.5%
- Net income
- +18.5%
- EPS
- +55.0%
- Free cash flow
- +24.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026